These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9348581)

  • 1. The UFT/leucovorin/etoposide regimen for the treatment of advanced gastric cancer. Oncopaz Cooperative Group.
    González Barón M; Espinosa E; Feliu J; Ordóñez A; Zamora P; de Castro J; García Girón C; García Alfonso P; Garrido P; Belón J; Lomas M
    Oncology (Williston Park); 1997 Sep; 11(9 Suppl 10):109-12. PubMed ID: 9348581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group.
    Feliu J; González Barón M; García-Girón C; Espinosa E; García-Alfonso P; Belón J; Blanco E; Garrido P; Ordónez A; Gómez-Navarro J; Zamora P
    Cancer; 1996 Jul; 78(2):211-6. PubMed ID: 8673994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma.
    Jeen YT; Yoon SY; Shin SW; Kim BS; Mok YJ; Kim CS; Hyun JH; Kim JS; Kim YH
    Cancer; 2001 Jun; 91(12):2288-93. PubMed ID: 11413517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II trial. Oral UFT and leucovorin in patients with advanced gastric carcinoma.
    Kim YH; Shin SW; Kim BS; Park YT; Kim JG; Kim JS
    Oncology (Williston Park); 1997 Sep; 11(9 Suppl 10):119-23. PubMed ID: 9348583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epirubicin, cisplatin, oral UFT, and calcium folinate in advanced gastric carcinoma.
    Kim YH; Kim BS; Seo JH; Choi CW; Kim JS; Chun HJ; Hyun JH; Kim JS
    Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):64-8. PubMed ID: 10442365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of cisplatin, epirubicin, UFT, and leucovorin (PELUF) as first-line chemotherapy in metastatic gastric cancer.
    Idelevich E; Karminsky N; Dinerman M; Katsenelson RL; Zvi NB; Baruch NB; Biran H; Man S; Shani A
    Acta Oncol; 2007; 46(3):324-9. PubMed ID: 17450467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of epirubicin, cisplatin and uracil-tegafur for advanced gastric carcinoma.
    Woo IS; Moon DH; Shim BY; Lee MA; Byun JH; Kim KW; Kang JH; Choi MG; Chung IS; Hong YS; Park SY; Lee KS
    Jpn J Clin Oncol; 2005 Jan; 35(1):13-7. PubMed ID: 15681598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience of Oncopaz Cooperative Group with oral fluoropyrimidines in tumors of the stomach, lung, head and neck, and breast.
    Feliu J; González Barón M; Zamora P; Garcia Alfonso P; Garcia Girón C; Blanco E; Belón J; Garrido P; Jara C; Ruiz A; Vincent JM; Espinosa E
    Oncology; 1997; 54 Suppl 1():30-7. PubMed ID: 8978582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma.
    Pazdur R; Lassere Y; Rhodes V; Ajani JA; Sugarman SM; Patt YZ; Jones DV; Markowitz AB; Abbruzzese JL; Bready B
    J Clin Oncol; 1994 Nov; 12(11):2296-300. PubMed ID: 7964943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uracil and tegafur modulated with leucovorin: an effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Oncopaz Cooperative Group.
    Feliu J; González Barón M; Espinosa E; García Girón C; de la Gándara I; Espinosa J; Colmenarejo A; Jalón JI; Fernández Y; de Castro J
    Cancer; 1997 May; 79(10):1884-9. PubMed ID: 9149013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL)--a very effective regimen with good patients' compliance for advanced gastric cancer.
    Cheng AL; Yeh KH; Lin JT; Hsu C; Liu MY
    Anticancer Res; 1998; 18(2B):1267-72. PubMed ID: 9615799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of Oral UFT and leucovorin in advanced gastric carcinoma.
    Kim YH; Cheong SK; Lee JD; Park JS; Shin SW; Kim JS
    Am J Clin Oncol; 1996 Apr; 19(2):212-6. PubMed ID: 8610653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. UFT modulated with leucovorin in advanced colorectal cancer: Oncopaz experience.
    González Barón M; Feliu J; Garcia Girón C; Espinosa J; Martinez B; Blanco E; Crespo MC; Ordóñez A; Espinosa E; de Castro J; Juárez F; Colmenarejo A
    Oncology; 1997; 54 Suppl 1():24-9. PubMed ID: 8978581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thymidylate synthase inhibition by an oral regimen consisting of tegafur-uracil (UFT) and low-dose leucovorin for patients with gastric cancer.
    Ichikura T; Tomimatsu S; Okusa Y; Yahara T; Uefuji K; Tamakuma S
    Cancer Chemother Pharmacol; 1996; 38(5):401-5. PubMed ID: 8765432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral UFT, etoposide and leucovorin in recurrent non-small cell lung cancer: a non-randomized phase II study.
    Surmont V; Aerts JG; Pouw E; Tan KY; Vernhout R; Gras J; Salomé J; Pronk T; Schmitz PI; Hoogsteden H; van Klaveren RJ
    Lung Cancer; 2009 Dec; 66(3):333-7. PubMed ID: 19327865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer.
    Hoff PM; Pazdur R; Benner SE; Canetta R
    Anticancer Drugs; 1998 Jul; 9(6):479-90. PubMed ID: 9877235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study with a combination of epirubicin, cisplatin, UFT, and leucovorin in advanced hepatocellular carcinoma.
    Kim SJ; Seo HY; Choi JG; Sul HR; Sung HJ; Park KH; Choi IK; Oh SC; Yoon SY; Seo JH; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS
    Cancer Chemother Pharmacol; 2006 Apr; 57(4):436-42. PubMed ID: 16049620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in a 3-times-daily regimen to treat patients with recurrent metastatic breast cancer.
    Hortobagyi GN; Heim W; Hutchins L; Rivera E; Mason B; Booser DJ; Kirshner J
    Cancer; 2010 Mar; 116(6):1440-5. PubMed ID: 20091835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary results. UFT/methotrexate/leucovorin for breast Ca patients in progression after HDCT/PBPC support.
    Martin M; Casado A; López-Martin JA; Rodriguez-Lescure A; Nieto Y; Ayala F; Diaz-Rubio E
    Oncology (Williston Park); 1997 Sep; 11(9 Suppl 10):83-5. PubMed ID: 9348575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and toxicity of lower dose UFT without leucovorin in metastatic gastric cancer patients.
    Somali I; Meydan N; Tarhan MO; Oztop I; Alacacioglu A; Yilmaz U
    J BUON; 2009; 14(3):429-33. PubMed ID: 19810134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.